by John A. Jenkins | Nov 2, 2023 | FDA, FOIA, Pharmaceuticals
In FOIAengine, Media Requests Seek the Answer When word leaked in late August that the Department of Health and Human Services recommended that marijuana should no longer be considered a dangerous drug, media organizations quickly responded with a flurry of Freedom of...
by John A. Jenkins | Oct 25, 2023 | FDA, FOIA, Litigation, Pharmaceuticals
In FOIAengine, a Slew of Requests About Ivermectin Robert Califf headed up the Food and Drug Administration during the last year of the Obama Administration. By the time Califf spun through the revolving door, returning to his old job early in 2022, he’d picked up...
by Randy E. Miller | Oct 18, 2023 | Cryptocurrency, FOIA, Politics, SEC
FOIAengine Analysis of SEC Requests Reveals Insights An analysis of Freedom of Information Act requests to the Securities and Exchange Commission over the past six months highlights investor interest in several of the leading storylines of the year, including the...
by John A. Jenkins | Oct 5, 2023 | Banking, FOIA, SEC, Short-Selling, Stock Market
FOIAengine: LA’s Steven Sugarman Goes After Carson Block and Muddy Waters Jason Galanis is Inmate 80739-198, currently locked up in a federal prison in Montgomery, Alabama. Galanis is a member of a notorious crime family, a recidivist white-collar criminal doing...
by John A. Jenkins | Sep 27, 2023 | Banking, Cryptocurrency, FOIA, SEC, Stock Market
FOIAengine: As Trial Looms, a Private Investigator Pursues the SEC It’s been a tough couple of months for Sam Bankman-Fried. He’s stewing in jail, facing 155 years in prison, while lawyers, accountants, and other experts rack up $700 million in fees from the crypto...
by Randy E. Miller | Sep 20, 2023 | FDA, FOIA, Hedge Funds, Pharmaceuticals, Short-Selling, Stock Market
FOIAengine Identifies 57 New FOIA Requests to FDA Hedge funds and other financial institutions made 57 Freedom of Information Act (FOIA) requests last month to the Food and Drug Administration (FDA) seeking information about adverse drug events and...
